Ron Finklestien

Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development Atai’s $50 Million Investment in Beckley Psytech’s Psychedelics Development

Biopharma and resources-pooling company Atai Life Sciences ATAI has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing...

Rare December Stock Selections from 34 Analysts Rare December Stock Selections from 34 Analysts

December saw a recent market surge even higher, with the S&P 500 notching gains of nearly +14% over the final 2 months of 2023. The question remains: are...

M-tron (MPTI) Hits 52-Week High: Here’s What’s Driving...

M-tron Industries, Inc. (MPTI) reached a new 52-week high of $41.62 on Jan 3. The stock pulled back to end the trading session at $36.23, down 1.5% from the previous...

Investors Cheer Positive Results in Atai Life Sciences MDMA Study Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD...

Biopharma firm Atai Life Sciences ATAI has announced the positive outcomes of a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, developed for the potential treatment of PTSD. Assessing EMP-01's safety, tolerability, pharmacokinetics (PK) and pharmacodynamics...

Mature Industrial Economy Faces Growth Deterioration in 2024 – Citi Mature Industrial Economy Faces Growth Deterioration in 2024 – Citi

Image Source: SlavkoSereda/iStock via Getty Images Oil markets have experienced a $15 drop in the past three months, stirring doubts about OPEC+'s ability to maintain or enforce set cuts. According to Max Layton, Citi's global head of...

The Whirlwind Rise of Wabtec (WAB): A Glimpse into What Fuels the Growth

Strong Growth and Raised Guidance Wabtec Corporation (WAB) has found itself riding high on the crest of a lucrative wave, largely due to the robust performance of its Freight segment. With an upward revision in...